1st Circ. Won't Rethink Nexium Pay-For-Delay Decision

Law360, New York (January 10, 2017, 5:52 PM EST) -- The First Circuit on Tuesday turned down bids by Nexium buyers for a rehearing of its November decision declining to revive a pay-for-delay class action against AstraZeneca and Ranbaxy over the heartburn medication.

End payors, direct purchasers and individual retailers had all asked the appeals court for either a rehearing by the original three-judge panel or a full-panel review of the case, but none of their requests had merit, the court said.

The direct purchasers and end payors had argued that the court’s ruling created a requirement for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.